Click on image to view larger version.

Fig. 6. PI3-kinase is involved in the progastrin-induced cytoplasmic shift of
ß-catenin. (A) Basal Src kinase activity (black bars), assessed as
described in the legend to Fig.
5, in IMGE-5 cells expressing a
SH2 dominant-negative
mutant of the p85 regulatory subunit of PI3-kinase
(IMGE-5/PI3-k-/-) (c) was similar to cells transfected with vector
only (VO) (a). Furthermore, activation of Src kinase activity by 5 nM
progastrin6-80 (b,d, white bars) was not PI3-kinase dependent. (B)
Treatment of IMGE-5/PI3-k-/- cells with 5 nM
progastrin6-80 induced a partial or complete disappearance from the
plasma membrane of ZO-1 and symplekin (SYM), respectively, compared with
untreated (U) controls. The disappearance was prevented by preincubation with
the Src kinase inhibitor PP2. Conversely, the cytoplasmic shift of
ß-catenin (ß-cat) induced by progastrin6-80 in wild-type
or IMGE-5/Src-/- cells was prevented in IMGE-5/PI3-k-/-
clones, as well as in IMGE-5/Src-/- cells preincubated with the
PI3-kinase inhibitor LY294002. In DLD-1/Src-/- cells, ZO-1 was
mostly located at the membrane, whereas DLD-1/PI3-k-/- cells showed
a largely cytoplasmic expression of E-cadherin (E-cad). Bar, 20 µm. (C)
When compared with untreated cells (U, black bars), 5 nM
progastrin6-80 (PG, white bars) induced a partial dissociation of
the occludin (Occl)/ZO-1 complex, assessed as described in the legend to
Fig. 1, in
IMGE-5/PI3-k-/- cells (left panel), of similar amplitude to that
observed in wild-type or IMGE-5/VO cells. However, dissociation of the
E-cadherin (E-cad)/ß-catenin (ß-cat) complex after
progastrin6-80 treatment, assessed as described in the legend to
Fig. 3, did not occur in
IMGE-5/PI3-k-/- clones (right panel). In A and C, densitometric
analysis represents the average of at least three experiments, and statistical
significance was assessed by Student's t test.
*P<0.05.